This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amylin, AIG: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Amylin Pharmaceuticals (AMLN) fell in late trades on Wednesday after the drug developer announced plans to sell additional common stock.

The company has yet to determine how many additional shares it plans to issue or at what price but by increasing the amount of outstanding stock, the holdings of existing shareholders will be correspondingly diluted.

In a regulatory filing, Amylin said it plans to use the proceeds of the offering for the "commercialization of BYDUREON, as well as for general corporate purposes which may include research and development expenses, capital expenditures, working capital and general administrative expenses."



The stock was last quoted at $15.41, down 4.7%, on volume of 232,000, according to Nasdaq.com. Based on Wednesday's regular-session close at $16.17, Amylin shares have soared 40% since the start of 2012, hitting a 52-week high of $18.45 on Feb. 17.

The company received approval of Bydureon, a weekly treatment for type 2 diabetes, on Jan. 27, and the drug became available by prescription in the United States on Feb. 13.

Check out TheStreet's quote page for Amylin for year-to-date share performance, analyst ratings, earnings estimates and much more.

AIG

Shares of insurance giant American International Group (AIG - Get Report) ticked lower in extended trades following news that the U.S. Treasury is selling $6 billion worth of its bailout-related holdings in the company.

The stock was last quoted at $29, down 1.5%, on volume of more than 3.4 million, according to Nasdaq.com.

AIG itself is expected to purchase up to $3 billion worth of the stock being sold by the Treasury, which will still have nearly $42 billion sunk into the company following its 2008 bailout. AIG shares are up more than 25% year-to-date.

Check out TheStreet's quote page for AIG for year-to-date share performance, analyst ratings, earnings estimates and much more.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AIG $61.85 -0.37%
HRB $29.88 0.91%
AAPL $126.00 -0.35%
FB $87.55 0.30%
GOOG $522.86 -0.10%

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs